Alcresta Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Alcresta Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013152
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alcresta Therapeutics Inc (Alcresta) develops and commercializes enzyme-based products for the treatment of gastrointestinal disorders and rare diseases. The company’s proprietary technology platform supports a pipeline of products that results in malabsorption common in cystic fibrosis, digestive cancers, and other serious diseases. It offers iLipase, to develop and market a range of novel, point of care, enzyme based products to support nutrition. Alcrestad’siLipase increases the absorption of fats crucial for growth and development, and improves the delivery, digestion and absorption of critical nutrients. The company also develops products indicated for exocrine pancreatic insufficiency caused by cystic fibrosis and other serious diseases. It caters to consumer and nutritional care markets. Alcresta is headquartered in Newton, Massachusetts, the US.

Alcresta Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Alcresta Therapeutics Raises USD10 Million in Venture Financing 10
Alcresta Raises USD49.4 Million Financing 11
Alcresta Raises US$10 Million In Series B Financing 12
Alcresta Raises US$10 Million In Series A Financing 14
Partnerships 16
Alcresta Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16
Alcresta Therapeutics Inc – Key Competitors 17
Alcresta Therapeutics Inc – Key Employees 18
Alcresta Therapeutics Inc – Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alcresta Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Alcresta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Alcresta Therapeutics Raises USD10 Million in Venture Financing 10
Alcresta Raises USD49.4 Million Financing 11
Alcresta Raises US$10 Million In Series B Financing 12
Alcresta Raises US$10 Million In Series A Financing 14
Alcresta Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16
Alcresta Therapeutics Inc, Key Competitors 17
Alcresta Therapeutics Inc, Key Employees 18

★海外企業調査レポート[Alcresta Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Malee Group Public Company Limited:企業の戦略・SWOT・財務分析
    Malee Group Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Malee Group Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • BDI – BioEnergy International AG:企業の戦略的SWOT分析
    BDI - BioEnergy International AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Exploration and Production KazMunaiGas (KMG):石油・ガス:M&Aディール及び事業提携情報
    Summary Exploration and Production KazMunaiGas (KMG EP), a subsidiary of National Company KazMunaiGas, is an upstream oil and gas company. The company carries out the exploration, development, production, processing and export of hydrocarbons and acquisition of oil and gas assets in Kazakhstan. Its …
  • Crossject SA (ALCJ)-医療機器分野:企業M&A・提携分析
    Summary Crossject SA (Crossject) is a medical device company that develops injection systems. The company offers products which include methotrexate, epinephrin, sumatriptan, L15, naloxone, apomorphine, and midazolam. It uses its needle-free injection system to develop a pipeline of supergenerics by …
  • BioMotiv LLC:医療機器:M&Aディール及び事業提携情報
    Summary BioMotiv LLC (BioMotiv) is a therapeutics licensing and development service provider. The company offers therapeutics across wide disease areas including proteins, small molecules, antibodies, and nucleotides. It portfolio includes psoriasis, inflammatory bowel diseases, cancer, retinitis pi …
  • Airgas, Inc.:戦略・SWOT・企業財務分析
    Airgas, Inc. - Strategy, SWOT and Corporate Finance Report Summary Airgas, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Augmenix Inc-医療機器分野:企業M&A・提携分析
    Summary Augmenix Inc (Augmenix) is a medical device company that develops space-filling hydrogels for radiation oncology and cancer surgery indications. The company offers products such as hydrogel products, space OAR systems, absorbable tissue marker, and trace-IT hydrogel products. Its TraceIT hyd …
  • Nectar Lifesciences Ltd (NECLIFE):企業の財務・戦略的SWOT分析
    Summary Nectar Lifesciences Ltd (NecLife) is a research driven pharmaceutical company that manufactures active pharmaceutical ingredients (APIs). The company provides contract research and manufacturing services such as process development and optimization, process scale up and validation, multi kil …
  • Penta-Ocean Construction Co Ltd:戦略・SWOT・企業財務分析
    Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Zhuhai Zhongfu Enterprise Company Limited:企業の戦略・SWOT・財務情報
    Zhuhai Zhongfu Enterprise Company Limited - Strategy, SWOT and Corporate Finance Report Summary Zhuhai Zhongfu Enterprise Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • British Columbia Cancer Agency:医療機器:M&Aディール及び事業提携情報
    Summary British Columbia Cancer Agency (BC Cancer Agency), a subsidiary of Provincial Health Services Authority is a healthcare service center that provides comprehensive cancer control program. The center offers services such as diagnostic and therapy planning, radiation therapy, patient assessment …
  • Merck & Co Inc (MRK):医療機器:M&Aディール及び事業提携情報
    Summary Merck & Co Inc (Merck) is a biopharmaceutical company that focuses on the discovery, development, manufacture and commercialization of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune …
  • Rollins Inc (ROL):企業の財務・戦略的SWOT分析
    Summary Rollins Inc (Rollins) is a consumer and commercial service provider that provides essential pest control services and protection against termite damage, rodents and insects. The company provides services through its international franchises. It also offers customized services to its clients …
  • Hanmi Pharmaceuticals Co Ltd (128940)-製薬・医療分野:企業M&A・提携分析
    Summary Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company’s prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counte …
  • BioScrip Inc (BIOS):企業の財務・戦略的SWOT分析
    BioScrip Inc (BIOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Sopharma AD (3JR):企業の財務・戦略的SWOT分析
    Sopharma AD (3JR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Senzime AB (SEZI):医療機器:M&Aディール及び事業提携情報
    Summary Senzime AB (Senzime) is a medical device company that develops patient-oriented monitoring systems. The company's product include TetraGraph monitor, CliniSenz analyzer, and Onzurf probe. Its TetraGraph monitor stimulates, measures, analyzes and displays muscle function in surgical patients …
  • Fugro GeoServices Ltd:企業の戦略的SWOT分析
    Fugro GeoServices Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Aurora National Life Assurance Company:企業の戦略・SWOT・財務情報
    Aurora National Life Assurance Company - Strategy, SWOT and Corporate Finance Report Summary Aurora National Life Assurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Nuclear Decommissioning Authority:企業の戦略的SWOT分析
    Nuclear Decommissioning Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆